This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Shettys team followed 252 patients who underwent the Ross procedure, a heartvalve replacement operation commonly used to treat younger patients with severe aortic valve disease. Three patients underwent the Ross-Konno procedure, in which the left-sided outflow root is enlarged to fit the pulmonary autograft. at 20 years.
In tricuspid valve regurgitation, a complex condition that Cedars-Sinai experts regularly treat, the valve between two heart chambers on the right side doesn't open or close properly. tim.hodson Tue, 02/18/2025 - 10:08 Feb. How has treatment for tricuspid valve disease evolved? Image by Getty.
As the pioneer in valve innovation for more than 60 years, Edwards believes it is uniquely positioned to lead this next frontier of aortic valve disease treatment. Edwards anticipates FDA approval of the JenaValve Trilogy HeartValve System in late 2025, which will represent the first approved therapy for patients suffering from AR.
In tricuspid valve regurgitation, a complex condition that Cedars-Sinai experts regularly treat, the valve between two heart chambers on the right side doesn't open or close properly. tim.hodson Tue, 02/18/2025 - 10:08 Feb. How has treatment for tricuspid valve disease evolved? Image by Getty.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content